An observational study in Tuberculosis, Tuberculosis, Pulmonary and Cavity, sponsored by University of Ulsan. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-25.
Sponsored by University of Ulsan · Observational
This study is a retrospective cohort study. The purpose of this study is to investigate clinical features of the patients with the cavitary pulmonary tuberculosis (TB) and endobronchial TB from the patients who have been registered in this hospital for treatment and follow-up, as part of the "PPM Project (Private-Public Mix project) for Korean National Tuberculosis Control" introduced in Korea since 2007.
Cavitary pulmonary tuberculosis (TB) is known to remain its Infectivity for a longer period of time than the non-cavitary pulmonary TB, which is usually almost inactivated its infectivity within two weeks after the administration of the anti - TB drugs.
However, there are few studies on this, so it is not known how long the infectivity persists, whether there is a correlation with the number of cavities or the size of the cavities between persistence of infectivity.
Meanwhile, endobronchial TB is known also to be highly infectious, unlike simple pulmonary TB.
It is not known how long infectivity can persist after the administration of anti-TB medication, and whether there is any difference in persistence of infectivity regarding the clinical characteristics of endobronchial TB.
In this study, investigators will analyze the retrospective data analysis of UUH-PPM Cohort, a cohort of PPM project patients in the Ulsan University Hospital (UUH).
The PPM project is a "Private-Public Mix project" for the eradication of tuberculosis from Korea, which the Korean government and private medical institutions have been conducting since 2007.
The patients who have been registered in this hospital for treatment and follow-up, as part of the "PPM Project (Private-Public Mix project) for Korean National Tuberculosis Control" introduced in Korea since 2007.
A. Cavitary Pulmonary TB Group
Inclusion Criteria:
Exclusion Criteria:
B. Endobronchial TB Group
Inclusion Criteria:
Exclusion Criteria:
The patients who are diagnosed with the cavitary pulmonary tuberculosis
Other: Observation of AFB smear/culture
The patients who are diagnosed with the endobronchial tuberculosis
Other: Observation of AFB smear/culture
Observation of the patients from group for their AFB smear/culture results
TLSD
Treatment of anti-TB medication to Last Smear positive Duration
Time frame: at baseline
TLCD
Treatment of anti-TB medication to Last Culture positive Duration
Time frame: at baseline
ACSD
AFB Culture-Smear positive Dissociation
Time frame: at baseline
TCV/RLV
TCV/RLV (Total Cavity\[ies\] Volume/Total Lung Volume) on enhance CT
Time frame: at baseline
TTV/RLV
TTV/RLV (Total TB lesion Volume/Total Lung Volume) on enhance CT
Time frame: at baseline
Radiological measure for Tb lesions including cavity size, number
analysis by BioView Duet Workstation (BioView Ltd, Rehovot, Israel) \[cavitary pulmonary TB\]
Time frame: at baseline
Admission Duration
The patients' Hospital admission duration \[cavitary pulmonary TB and endobronchial TB\]
Time frame: at baseline
Isolation Duration
The patients' isolation duration during hospital admission \[cavitary pulmonary TB and endobronchial TB\]
Time frame: at baseline
Hemoptysis /Bronchial artery embolization (BAE)
The patients' history of Hemoptysis /Bronchial artery embolization (BAE) \[cavitary pulmonary TB and endobronchial TB\]
Time frame: at baseline
TB PCR, XPERT
The patients' result of TB PCR, XPERT \[cavitary pulmonary TB and endobronchial TB\]
Time frame: at baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ulsan